|
1
|
Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
|
J Clin Endocrinol Metab
|
2005
|
1.94
|
|
2
|
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
|
J Clin Endocrinol Metab
|
1998
|
1.19
|
|
3
|
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
|
J Clin Endocrinol Metab
|
2001
|
0.97
|
|
4
|
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
|
J Bone Miner Res
|
1999
|
0.78
|
|
5
|
Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers.
|
Clin Pharmacol Ther
|
2010
|
0.78
|
|
6
|
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
|
Clin Pharmacol Ther
|
2001
|
0.76
|
|
7
|
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
|
J Bone Miner Res
|
1998
|
0.75
|